MATERIALS AND METHODS

Patients

This was a single institute, prospective, observational study conducted over 2 years. Consecutive patients with newly diagnosed NSCLC with adenocarcinoma or squamous cell carcinoma (SqCC) histology were considered for inclusion in this study. Subjects with a biopsy sample insufficient for the necessary histopathological analyses were excluded from the study.

Histopathological examination

All specimens were processed for paraffin sections for routine hematoxylin and eosin (H&E) staining and immunohistochemistry. The specimens included lung biopsies (bronchoscopic biopsies and computed tomography [CT]/positron emission tomography (PET)–guided biopsies) and biopsies from metastatic sites (lymph nodes, pleura, bone, and brain). Cytology samples were not included in the study. Based on H&E, the tumors were categorized as adenocarcinoma or SqCC as defined by the 2015 World Health Organization classification of lung tumors [11]. Tumors in which histological subtyping on the basis of routine H&E staining was difficult, immunohistochemistry with p63, thyroid transcription factor 1, cytokeratin (CK) 5/6, CK7, neuron-specific enolase, and CD56 was used.

Tumor-infiltrating lymphocytes

The TILs were evaluated based on morphology on H&E-stained slides. Only lymphocytes and plasma cells were included in the scoring. Necrotic areas within the tumor and alveolar macrophages were not included in the scoring [12]. TILs were assessed in five areas of the tumor to determine the mean TIL score. The TIL score was assigned based on the proportion of tumor stroma occupied by TILs (TIL0, 0 to ≤ 5%; TIL1, > 5% to ≤ 25%; TIL2, > 25 to ≤ 50%; TIL3, > 50%). Subjects with a score of TIL0 were considered to have low TILs and subjects with a score of TIL2 or TIL3 were considered to have high TILs.

PD-L1 expression

PD-L1 expression in tumors was assessed using immunohistochemistry with rabbit monoclonal antibody (SP263) on the Ventana automated immunostainer. Detection was optimized with the OptiView DAB IHC Detection Kit (Ventana Medical Systems, Tucson, AZ, USA). For positive controls, sections of the human placenta, as recommended in the data sheet of SP263 antibody (Fig. 1A) as well as human tonsil, were included in each batch. A negative control was run for each case. At least 100 viable tumor cells were scored. Tumor cells were considered to express PD-L1 when they showed complete or partial membranous staining with or without cytoplasmic staining of any intensity. PD-L1 expression on tumor cells was assigned scores based on the proportion of tumor cells (TC0, 0 to < 1%; TC1, ≥ 1 to ≤ 50%; TC2, > 50%) expressing PD-L1. Tumors with a PD-L1 expression on tumor cells > 50% (TC2) were considered PDL1–positive.

Mutation analysis

Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements were evaluated in subjects with adenocarcinoma histology. EGFR mutation analysis was performed using real-time PCR (EnteroGen, Agility Biotech, Los Angeles, CA, USA). ALK rearrangements were identified on immunohistochemistry performed on a Ventana BenchMark XT automated slide-processing system using the D5F3 clone [13].

Clinical details

The following clinical parameters were recorded at baseline: age, sex, smoking status, body mass index, performance status, and TNM. Performance status was evaluated using the Eastern Cooperative Oncology Group scale [14]. Contrast-enhanced CT scan of the thorax and upper abdomen (including the liver and adrenals) or whole-body PET was obtained for baseline staging evaluation in all patients. Tumor staging was performed using the seventh edition of the American Joint Committee on Cancer (AJCC) TNM classification [15]. Tumor staging was also performed using the eighth edition of the AJCC TNM classification in 106 patients (Supplementary Table S1). Because the proportion of patients between the seventh and eighth edition of the AJCC TNM classification was not significantly different, and to ensure completeness of data, the staging in the seventh edition of the AJCC TNM classification was used in the present study.

Subjects were treated with chemotherapy, targeted therapy, immunotherapy, radiotherapy, or surgery as indicated by tumor histopathology, mutation status, and clinical status, as previously described [16]. Briefly, subjects with adenocarcinoma without any driver mutation were treated with pemetrexed-based platinum doublet followed by maintenance pemetrexed therapy until disease progression [17]. Subjects with squamous histology were treated with docetaxel or gemcitabine-based platinum doublet. All patients receiving chemotherapy were administered at least four cycles of chemotherapy before response assessment using the Response Evaluation Criteria in Solid Tumors ver. 1.0 [18]. Subjects with sensitizing EGFR mutation or ALK rearrangement were treated with appropriate EGFR tyrosine kinase or ALK inhibitors, respectively [19,20].

Statistical analysis

Continuous variables were expressed as the mean and standard deviation and categorical values were expressed as the numbers and percentages. The differences between continuous and categorical variables were analyzed using the Mann-Whitney U test and the chi-square test (or Fisher exact test), respectively. Overall survival (OS) was defined as the time between initial diagnosis and date of death or last follow-up. The cutoff date for survival analysis was November 30, 2018. Survival curves were generated using the Kaplan-Meir method and were compared using the log-rank test. Multivariate analysis to identify predictors of survival was performed using the Cox proportional hazard model. Statistical analyses were performed using the commercial statistical package SPSS (IBM SPSS Statistics, ver. 22, IBM Corp., Armonk, NY, USA). A p-value < 0.05 was considered statistically significant.

RESULTS

A total of 128 cases of NSCLC were included in the present study (Table 1); 103 (80.5%) were males and the median age of the study population was 61 ± 15 years. The majority of patients had advanced disease (84.1% were stage IIIB/IV) and 44.8% of the patients had extrathoracic disease at diagnosis. Tissue samples (small biopsies: endobronchial biopsies, transbronchial biopsies, and imaging-guided core biopsies) were predominantly obtained from the lung (82.4%) and metastatic lymph nodes (8%), and 9.6% were resection samples. Adenocarcinoma and SqCC were observed in 52.3% and 47.7% of the subjects, respectively. A larger proportion of patients who were younger, female, non-smokers, and presented with advanced disease had adenocarcinoma. EGFR and ALK alterations were observed in 6.2% and 5.4% of the subjects, respectively. Chemotherapy (74.2%) was the most commonly used first-line therapy. Due to economic constraints, PD-L1–targeted therapy despite PD-L1 expression could not be provided to any patient in this study.

Based on immunohistochemistry, the majority of patients had PD-L1 expression on < 1% of tumor cells (TC0, 61.7%) (Table 2, Fig. 1). PD-L1 expression on ≥ 1% of tumor cells (TC1 or TC2) was observed in 38.3% of the subjects. However, this did not differ between subjects with adenocarcinoma or SqCC (p = .335). TIL1 (31.3%) and TIL0 (23.4%) were the most commonly observed TIL scores (Table 2, Fig. 2). High TILs (TIL occupying > 25% of tumor stroma, TIL2 or TIL3) were observed in 26.6% of patients. Infiltration > 50% of tumor stroma by TILs (TIL3) occurred in the least number of cases (7.8%). Difference in the TIL scores between adenocarcinoma and SqCC was not observed (p = .126). The baseline characteristics were not different between subjects with high and low TILs (data not shown). A higher proportion of patients with PD-L1 expression ≥ 1% on tumor cells (TC1 or TC2: 58.8% vs. 35.7%, p = .026) had high TILs than low TILs.

A total of 22 subjects (17.2%) were classified as PD-L1–positive (PD-L1 expression on tumor cells > 50%, TC2). Most of the clinical characteristics of PD-L1–positive subjects were not different from PD-L1–negative subjects (Table 3). However, subjects who were PD-L1–positive had a higher prevalence of liver metastasis at baseline (18.2% vs. 2.8%; p = .018). PD-L1–positive subjects were also more often diagnosed based on extrapulmonary biopsies (Table 3). The median OS (95% confidence interval [CI]) was 7.6 (6.5–8.8) months in subjects who were PDL1–negative compared with 8.5 (1.1–16.0) months in subjects who were PD-L1–positive (log-rank p = .584) (Fig. 3). On multivariate analysis, sex was the only factor associated with survival (hazard ratio, 0.39; 95% CI, 0.16 to 0.98; p = .046) (Table 4). The survival of patients with tumors showing high TILs was not different from subjects with low TILs (data not shown).

DISCUSSION

In this study, 17.2% of the patients with NSCLC could be labelled as PD-L1–positive (PD-L1 expression on tumor cells > 50%). PD-L1 expression ≥1% on tumor cells was observed in 38.3% of the subjects. PD-L1–positive subjects had a higher prevalence of liver metastasis and were more often diagnosed using biopsy samples obtained from extrapulmonary sites. The PD-L1 expression did not affect survival in the study population. High TILs (TILs occupying > 25% of tumor stroma) were observed in 26.6% of the subjects, however, it did not affect survival. A larger proportion of patients with higher PD-L1 expression on tumor cells was more associated with subjects with high TILs than low TILs.

The assessment of PD-L1 expression based on immunohistochemistry is complicated by several factors including intra-tumor heterogeneity and inter-assay variation [21]. Therefore, the estimated prevalence of PD-L1–positive NSCLCs varies widely (7%–75%) [5,22,23]. In the multinational EXPRESS study, PD-L1 expression on ≥ 50% and ≥ 1% of tumor cells was observed in 22% and 52% of patients with advanced NSCLC, respectively, using the 22C3 pharmDx kit [6]. In the present study, PD-L1 positivity was observed in 17.2% of NSCLCs (38.3% had PDL1 expression ≥ 1% on tumor cells). The SP263 antibody clone was used because its performance is comparable or better than the other available antibody clones [24–26]. In prior studies from India, a PD-L1 positivity rate of 27% (> 5% PD-L1 expression on tumor cells) and 34% (≥ 1% PD-L1 expression on tumor cells) was reported using the SP142 and SP263 clones, respectively [7,8]. Overall, the reported rates of PD-L1 expression in lung cancer in India appears to be less than international estimates. Whether this difference is due to methodological differences or true geographic differences is unclear.

PD-L1 expression has been associated with male sex, smoking, advanced tumor stage, SqCC histology, and EGFR mutation [5,22,27,28]. In the present study, association between PD-L1 expression and sex, smoking, or TNM stage, was not found. Liver metastasis was more common in subjects who were PD-L1–positive. The PD-L1 positivity rate was not affected by histology.

The association between PD-L1 expression and survival is controversial [5,7,22]. In a meta-analysis of 41 studies, PD-L1 expression was associated with poor survival in NSCLCs, specifically in subgroups of patients with adenocarcinoma or early disease [5]. In contrast, another study showed that PD-L1 expression resulted in worse prognosis in SqCC but not adenocarcinoma [22]. Furthermore, in another study, PD-L1 positivity in immune cells was found associated with better prognosis in resected NSCLCs [7]. In the present study, PD-L1 expression was not associated with survival.

Infiltration ≥ 20% of tumor stroma with TILs has been observed in 50% of subjects with NSCLCs [26]. Higher TILs have been associated with higher PD-L1 expression and better survival in NSCLCs [9,10,29]. In the present study, approximately one-fourth of the tumors showed high TILs (infiltration > 25% of tumor stroma by lymphocytes TIL2 or TIL3). Although high TILs were associated with higher PD-L1 expression in both TILs and tumor cells, high TILs did not affect survival in our study cohort.

This was a single-center study with a relatively small sample size, thus, the results, especially subgroup analyses, should be interpreted cautiously. The TNM stage was not a prognostic factor in the present study for several reasons. The study had a relatively small sample size (n = 128). A disproportionately larger proportion of patients had stage IV disease (62.7% with stage IV disease in this study compared with 51.1% with stage IV disease in a previous analysis from our center with a much larger sample size (n = 1,501) [14]. The EGFR and ALK positivity rate observed in this study was considerably lower than what is generally observed at our center possibly due to selection bias [30]. Subjects who had undergone mutation testing could have been excluded from this study because they might have been left with inadequate tissue specimen for additional histopathological analyses. Furthermore, a considerable proportion of lung cancer patients diagnosed based on cytology samples were not included in this study.

In conclusion, the present study results showed PD-L1 positivity and high TILs can be observed in approximately one-fifth and one-fourth of the patients with NSCLC, respectively. However, PD-L1 expression or high TILs did not affect the OS in our study cohort.

Supplementary Information

jptm-2021-08-08-Suppl.pdf

Fig. 1

Photomicrographs (programmed death-ligand 1 [PD-L1] staining using SP263 clone) showing positive control (PD-L1 staining in placenta) (A), TC2 (PD-L1 expression on > 50% of tumor cells [TCs]) (B), TC1 (PD-L1 expression on 1%–50% TCs) (C), and TC0 (PD-L1 expression on < 1% of TCs) (D).

Fig. 2

Photomicrographs (× 200) of hematoxylin and eosin staining showing TIL0 (0%–5% of tumor stroma occupied by tumor-infiltrating lymphocytes [TILs]) (A), TIL3 (> 50% of tumor stroma occupied by TILs) (B).

Fig. 3

Kaplan-Meir plots for overall survival (OS). OS of programmed death-ligand 1 (PD-L1)–positive subjects was not different from PD-L1–negative subjects. The median (95% confidence interval) OS was 7.6 months (6.5–8.8) in subjects who were PDL1–negative compared with 8.5 months (1.1–16.0) in subjects who were PD-L1-positive (log-rank p = .584).

REFERENCES

• 1. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019; 393: 1819-30. PubMed
• 2. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288-301. ArticlePubMed
• 3. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078-92. PubMed
• 4. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018; 379: 2040-51. ArticlePubMed
• 5. Zhang M, Li G, Wang Y, et al. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep 2017; 7: 10255.ArticlePubMedPMCPDF
• 6. Dietel M, Savelov N, Salanova R, et al. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter EXPRESS study. Lung Cancer 2019; 134: 174-9. ArticlePubMed
• 7. Vallonthaiel AG, Malik PS, Singh V, et al. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: a report from India. Ann Diagn Pathol 2017; 31: 56-61. ArticlePubMed
• 8. Kumar M, Guleria B, Swamy S, Soni S. Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer. Lung India 2020; 37: 145-50. ArticlePubMedPMC
• 9. Brambilla E, Le Teuff G, Marguet S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J Clin Oncol 2016; 34: 1223-30. ArticlePubMedPMC
• 10. Bremnes RM, Busund LT, Kilvaer TL, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol 2016; 11: 789-800. ArticlePubMed
• 11. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015; 10: 1243-60. PubMed
• 12. Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 2017; 24: 311-35. ArticlePubMedPMC
• 13. Bal A, Singh N, Agarwal P, Das A, Behera D. ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India. APMIS 2016; 124: 832-8. ArticlePubMedPDF
• 14. Prasad KT, Kaur H, Muthu V, Aggarwal AN, Behera D, Singh N. Interconversion of two commonly used performance tools: an analysis of 5844 paired assessments in 1501 lung cancer patients. World J Clin Oncol 2018; 9: 140-7. ArticlePubMedPMC
• 15. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-14. ArticlePubMed
• 16. Singh N, Aggarwal AN, Behera D. Management of advanced lung cancer in resource-constrained settings: a perspective from India. Expert Rev Anticancer Ther 2012; 12: 1479-95. ArticlePubMed
• 17. Prasad KT, Muthu V, Biswas B, et al. Utility and safety of maintenance chemotherapy in advanced non-small cell lung cancer across various performance status categories: real-world experience. Curr Probl Cancer 2020; 44: 100565.ArticlePubMed
• 18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16. PubMed
• 19. Garg A, Batra U, Choudhary P, et al. Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: a real-world multicentric cohort analysis from India. Curr Probl Cancer 2020; 44: 100570.ArticlePubMed
• 20. Patel A, Batra U, Prasad KT, et al. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: a multicenter study from India. Curr Probl Cancer 2020; 44: 100571.ArticlePubMed
• 21. McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2016; 2: 46-54. ArticlePubMedPMC
• 22. Sorensen SF, Zhou W, Dolled-Filhart M, et al. PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy. Transl Oncol 2016; 9: 64-9. ArticlePubMedPMC
• 23. Calles A, Liao X, Sholl LM, et al. Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer. J Thorac Oncol 2015; 10: 1726-35. ArticlePubMed
• 24. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol 2017; 12: 208-22. ArticlePubMed
• 25. Parra ER, Villalobos P, Mino B, Rodriguez-Canales J. Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol 2018; 26: 83-93. ArticlePubMed
• 26. Kim H, Kwon HJ, Park SY, Park E, Chung JH. PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. Oncotarget 2017; 8: 98524-32. ArticlePubMedPMC
• 27. Mandarano M, Bellezza G, Belladonna ML, et al. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. Virchows Arch 2019; 474: 159-68. ArticlePubMedPDF
• 28. He Y, Rozeboom L, Rivard CJ, et al. PD-1, PD-L1 protein expression in non-small cell lung cancer and their relationship with tumor-infiltrating lymphocytes. Med Sci Monit 2017; 23: 1208-16. ArticlePubMedPMC
• 29. Geng Y, Shao Y, He W, et al. Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis. Cell Physiol Biochem 2015; 37: 1560-71. ArticlePubMedPDF
• 30. Muthu V, Bal A, Gupta N, Prasad K, Behera D, Singh N. P2.03-053 A five-year audit of EGFR and ALK testing at a tertiary care centre in North India: more sensitive methods do make a difference! J Thorac Oncol 2017; 12: S2395.Article

Figure & Data

References

Citations

Citations to this article as recorded by  

• Multiplex plasma protein assays as a diagnostic tool for lung cancer
  Mohammad Tanvir Ahamed, Jenny Forshed, Adrian Levitsky, Janne Lehtiö, Amanj Bajalan, Maria Pernemalm, Lars E. Eriksson, Björn Andersson
  Cancer Science.2024; 115(10): 3439.     CrossRef
• Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study
  Prudence A. Russell, Alexandra L. Farrall, Sarita Prabhakaran, Khashayar Asadi, Wade Barrett, Caroline Cooper, Wendy Cooper, Samuel Cotton, Edwina Duhig, Matthew Egan, Stephen Fox, David Godbolt, Shilpa Gupta, Aniza Hassan, Connull Leslie, Trishe Leong, D
  Pathology.2023; 55(7): 922.     CrossRef